Total Price: $0.00
Contact Information
Recombinant Human VCAM1 Protein (Fc Tag)(Active)
SKU: PKSH031863-100
Recombinant Human VCAM1 Protein (Fc Tag)(Active)
| SKU # | PKSH031863 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | CD106, INCAM-100, L1CAM, V-CAM 1, VCAM-1, VCAM1, Vascular Cell Adhesion Protein 1 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Pro 697 |
| Accession | NP_001069.1 |
| Calculated Molecular Weight | 101 kDa |
| Observed Molecular Weight | 130-140 kDa |
| Tag | C-hFc |
| Bio-activity | Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells. When cells are added to VCAM1 coated plates (10 μg/mL, 100 μL/well) approximately > 70% cells will adhere after 1 hour of incubation at 37℃. |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.